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Abstract
Introduction Medulloblastoma is a malignant embryonal tumor of the cerebellum that occurs predominantly in children. 
To find germline genetic variants associated with medulloblastoma risk, we conducted a genome-wide association study 
(GWAS) including 244 medulloblastoma cases and 247 control subjects from Sweden and Denmark.
Methods Genotyping was performed using Illumina BeadChips, and untyped variants were imputed using IMPUTE2.
Results Fifty-nine variants in 11 loci were associated with increased medulloblastoma risk (p < 1 × 10–5), but none were 
statistically significant after adjusting for multiple testing (p < 5 × 10–8). Thirteen of these variants were genotyped, whereas 
46 were imputed. Genotyped variants were further investigated in a validation study comprising 249 medulloblastoma cases 
and 629 control subjects. In the validation study, rs78021424 (18p11.23, PTPRM) was associated with medulloblastoma 
risk with OR in the same direction as in the discovery cohort  (ORT = 1.59,  pvalidation = 0.02). We also selected seven medul-
loblastoma predisposition genes for investigation using a candidate gene approach: APC, BRCA2, PALB2, PTCH1, SUFU, 
TP53, and GPR161. The strongest evidence for association was found for rs201458864 (PALB2,  ORT = 3.76, p = 3.2 × 10–4) 
and rs79036813 (PTCH1,  ORA = 0.42, p = 2.6 × 10–3).
Conclusion The results of this study, including a novel potential medulloblastoma risk loci at 18p11.23, are suggestive but 
need further validation in independent cohorts.
Keywords Pediatric cancers · CNS cancers · Adolescents and young adults (AYA) · Epidemiology · Genetics of risk, 
outcome, and prevention
Introduction
Medulloblastoma is the most common embryonal central 
nervous system malignancy in children. It is well known 
that a fraction of all cases is caused by germline mutations 
in TP53 (underlying Li-Fraumeni syndrome), APC (underly-
ing Turcot syndrome), or PTCH1/PTCH2/SUFU (underlying 
basal cell nevus/Gorlin, syndrome) [1, 2]. A recent study 
including 1022 medulloblastoma patients found that 6% of 
all cases had a germline mutation in TP53, APC, PTCH1, 
SUFU, or in two additional genes with presumed tumor 
suppressor function: BRCA2 or PALB2 [3]. Another recent 
study reported a novel medulloblastoma predisposition gene 
in GPR161 [4]. The somatic genetic changes that occur in 
sporadic medulloblastoma tumors are also well-described, 
including alterations in CCND2, CTNNB1, DDX3X, GLI2, 
SMARCA4, MYC, MYCN, PTCH1, TP53, and KMT2D 
[5]. Although we know much about genetic aberrations in 
medulloblastoma tumors and the genetic syndromes that pre-
dispose to the disease, little is known about how common 
germline genetic variants (i.e. single nucleotide polymor-
phisms, SNPs) contribute to medulloblastoma susceptibility.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1106 0-020-03424 -9) contains 
supplementary material, which is available to authorized users.
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Prognosis for medulloblastoma patients is poor, with a 
ten-year survival rate of 63% [6]. As a consequence of the 
disease and intensive treatment, the children who survive 
have an increased risk of long-term neurocognitive dysfunc-
tion and secondary malignancies [7]. To improve treatment 
and prevention strategies for this devastating disease, a better 
understanding of medulloblastoma etiology is needed. We 
have conducted a genome-wide association study (GWAS) 
with the aim to identify genetic variants that are associated 
with medulloblastoma development in children and young 
adults. Identifying genetic variants that predispose to medul-
loblastoma development may provide new insights into the 
genetic pathways that contribute to the development of the 
disease and potential new targets for therapy.
Results
To find germline genetic variants associated with medul-
loblastoma risk, we conducted a genome-wide scan of 244 
medulloblastoma cases and 247 control subjects from Swe-
den and Denmark that fulfilled the inclusion criteria (Figure 
S1; Table S1). Tests of association with medulloblastoma 
risk were performed for 1,288,472 SNPs that passed qual-
ity control. The Q–Q plot and inflation factor ʎ indicated 
no significant effect on the results by population stratifica-
tion (Figure S2). Thirteen genetic variants in six genomic 
loci were associated with increased medulloblastoma risk 
(p < 1 × 10–5), but none were statistically significant when 
applying a conservative p-value threshold to adjust for mul-
tiple testing (p < 5 × 10–8; Table 1). We were able to analyze 
12 of these variants in a validation cohort consisting of 249 
cases and 629 controls (Table S1). In the validation cohort, 
one genetic variant, rs78021424 (18p11.23, PTPRM), was 
associated with medulloblastoma risk with an OR in the 
same direction as in the discovery cohort (Table 1).
In a search for SNPs with even stronger associations 
at the 18p11.23 locus, and to find additional interesting 
regions, we imputed SNPs in the discovery dataset and 
performed association analyses of an additional 7,916,089 
SNPs (Fig. 1). Forty-six imputed SNPs in eight genomic 
loci were associated with medulloblastoma risk (p < 1 × 10–5; 
Table S2). These associations were not, however, statistically 
significant after adjusting for multiple testing. The SNP with 
the strongest association in the 18p11.23 (PTPRM) locus 
was rs185966860  (ORper A allele = 4.01, 95% CI 2.43–6.63, 
p  = 5.97 × 10–8).
In addition to genome-wide analyses, we were spe-
cifically interested in seven genes, namely: APC, BRCA2, 
PALB2, PTCH1, SUFU, TP53, and GPR161 [3, 4]. Within 
these seven candidate genes, the strongest evidence for asso-
ciation was found for rs201458864, located within PALB2 
 (ORper T allele = 3.76, 95% CI 1.83–7.75, p = 3.2 × 10–4) and 
rs79036813, located within PTCH1  (ORper A allele = 0.42, 95% 
CI 0.24–0.74, p = 2.6 × 10–3) (Figure S3).
Discussion
In this first GWAS of medulloblastoma, we found a poten-
tial medulloblastoma risk locus at 18p11.23. Medulloblas-
toma is a rare disease, which makes it challenging to collect 
enough samples for adequate statistical power, especially 
for a GWAS. Compared to other epidemiologic studies of 
medulloblastoma, the number of cases included in this study 
is large. However, in relation to the number of statistical 
tests performed, the number of cases is still small, and our 
study was not powered to detect associations with a small 
Table 1  Top SNPs from association analyses of 1,288,472 directly genotyped SNPs
SNP Major/
minor allele
Discovery Validation
maf controls/cases OR 95% CI p-value OR p-value loci (genes within 30,000 bp)
rs853362 A/G 0.142/0.262 2.06 1.51–2.83 6.49 × 10–6 1.19 0.2546 6p23 (CD83)
rs853372 G/A 0.142/0.26 2.05 1.49–2.82 9.18 × 10–6 1.13 0.4184 6p23 (CD83)
rs10266582 C/T 0.152/0.059 0.32 0.21–0.50 2.41 × 10–7 1.46 0.0302 7q21.11 (MAGI2)
rs17404544 T/C 0.063/0.143 2.58 1.70–3.93 9.05 × 10–6 1.33 0.3677 8p23.2 (CSMD1)
rs80012312 A/G 0.002/0.053 7.35 3.31–16.30 9.25 × 10–7 n.a n.a 8q24.12
rs7077776 A/C 0.245/0.373 1.85 1.41–2.43 9.92 × 10–6 1.07 0.5842 10q26.2 (DOCK1)
rs11661715 A/G 0.036/0.109 3.83 2.28–6.43 3.67 × 10–7 1.04 0.8652 18p11.23 (PTPRM)
rs11873445 C/T 0.04/0.119 3.91 2.37–6.45 9.55 × 10–8 1.15 0.5116 18p11.23 (PTPRM)
rs12185387 A/G 0.043/0.121 3.63 2.23–5.90 2.24 × 10–7 1.04 0.8364 18p11.23 (PTPRM)
rs12956144 T/C 0.04/0.117 3.81 2.30–6.30 1.87 × 10–7 1.03 0.8908 18p11.23 (PTPRM)
rs78021424 C/T 0.04/0.115 3.77 2.27–6.25 2.81 × 10–7 1.59 0.0209 18p11.23 (PTPRM)
rs1468707 G/A 0.043/0.117 3.69 2.23–6.09 3.29 × 10–7 1.03 0.8975 18p11.23 (PTPRM)
rs1942957 A/G 0.043/0.117 3.69 2.23–6.09 3.29 × 10–7 1.05 0.8095 18p11.23 (PTPRM)
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effect size. Although GWAS of adult cancers usually report 
associations with small effect sizes, studies of early onset 
malignancies have reported associations with larger effects 
[8]. Analogous with this, for the majority of associations 
with p < 1 × 10–5 in this study, effect sizes were large, and 
carriers of the risk allele had a more than two-fold increased 
risk. Our findings were not statistically significant when 
using the p value threshold p < 5 × 10–8 to correct for mul-
tiple comparisons. Although a stringent p-value threshold 
is required in GWAS to reduce the presence of false posi-
tive findings, strict Bonferroni correction may be considered 
overly conservative due to linkage disequilibrium between 
many genetic variants. Twelve variants with evidence for 
associations in the initial analyses were investigated in an 
additional cohort. One of these SNPs, located in 18p11.23 
(PTPRM) showed suggestive evidence for an association 
with medulloblastoma risk also in the validation cohort. 
The PTPRM gene product is a receptor-type protein tyros-
ine phosphatase that mediates cell–cell adhesion. Altered 
expression, mutations, or aberrant methylation of PTPRM 
have been described in different malignancies, including 
glioblastoma [9]. The role of PTPRM in medulloblastoma is, 
to our knowledge, unknown, but it is interesting to note that 
the PTPRM protein has been shown to interact with beta-
catenin [10]. Beta-catenin is a central part of the Wnt signal-
ing pathway and is encoded by the gene CTNNB1, which is 
frequently mutated in WNT medulloblastoma [5]. However, 
only about 10% of all medulloblastoma tumors belong to 
the WNT subgroup [5], and this subgroup is therefore rep-
resented by few patients in the study cohort. Investigation of 
imputed variants across the genome indicated the presence 
of additional variants associated with medulloblastoma risk 
in the 18p11.23 locus and variants in five additional genetic 
regions that remain to be validated in an independent cohort.
Germline mutations in APC, BRCA2, PALB2, PTCH1, 
SUFU, and TP53 occur in up to 6% of all medulloblastoma 
cases [3]. Another potential medulloblastoma predispos-
ing mutation has been reported in the gene GPR161 [4]. In 
candidate gene analysis restricted to these seven genes, we 
observed associations between genetic variants in PALB2 
and PTCH1 and medulloblastoma risk. Pathogenic genetic 
variants in PALB2 have been associated with increased 
risk of medulloblastoma as well as breast cancer [3, 11]. 
Genetic testing of PALB2 has been suggested for clinical 
testing in breast cancer families and in specific subgroups 
of medulloblastoma based on clinical and molecular tumor 
characteristics [3, 12]. Germline mutations in PTCH1 give 
rise to basal cell nevus (Gorlin) syndrome, which comes 
with an increased risk of different malignancies, including 
basal cell carcinoma and medulloblastoma. In the present 
study, we investigated common germline genetic variants 
(minor allele frequency > 1%), and we could not assess the 
rare germline mutations in PALB2 and PTCH1 reported by 
Waszak et al. [3].
Medulloblastoma tumors comprise four or more molecu-
lar subgroups [5]. The cases in our discovery sets were diag-
nosed during a period when these molecular subgroups of 
medulloblastoma were not established. In the present study, 
tissue samples are not possible to obtain, and molecular sub-
groups cannot be taken into consideration in the analyses, 
Fig. 1  Manhattan plot. P-values for the association between 9,204,561 genetic variants and medulloblastoma risk. Both genotyped and imputed 
SNPs are included. Solid line indicates genome-wide statistical significance (p = 5 × 10–8). Dashed line indicates p = 1 × 10–5
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which is a limitation of the study. In GWAS of glioma, which 
is also a heterogeneous group of brain tumors, we and others 
have shown that many established risk loci are specific for 
certain subtypes [13, 14]. However, even in early GWAS of 
glioma, in which all glioma were included, we found sev-
eral genetic variants that were associated with an increased 
risk of all glioma, irrespective of molecular subtype [15]. 
Another potential limitation of the study is the inclusion of 
study subjects from six different countries in the validation 
phase, whereas patients and control subjects in the discovery 
phase were born in either Sweden or Denmark.
An advantage of the study is that, although cases were 
retrospectively identified, their blood samples were col-
lected prior to disease diagnosis. With this study design, we 
avoided survival bias, which can be a problem in a case–con-
trol study of an aggressive disease, where mortal cases 
would be underrepresented. On the contrary, we may have 
an underrepresentation of less aggressive medulloblastoma, 
since a subset of surviving cases chose not to participate in 
the study.
In summary, we have identified 11 loci that may be asso-
ciated with medulloblastoma development in children and 
young adults, including the 18p11.23 (PTPRM) loci that was 
validated in a separate cohort. None of the observed asso-
ciations were, however, statistically significant after con-
servative correction for multiple testing, and to know the 
relevance of these loci in medulloblastoma etiology, replica-
tion in independent cohorts is needed. If these associations 
proves robust in independent validations, it is a step towards 
enhanced understanding of medulloblastoma etiology, which 
in turn may enable development of improved treatment and 
prevention strategies. For sufficient power of future studies 
of genetic variants in medulloblastoma, broad international 
collaborations are required.
Materials and methods
Study subjects
Medulloblastoma cases diagnosed between 1975 and 2008, 
under the age of 25, were identified from the national cancer 
registries in Sweden (n = 136) and Denmark (n = 128) [16] 
(Table S1). Dried blood spot samples were collected from 
the Swedish Phenylketonuria Screening Registry [17] and 
the Danish Newborn Screening Biobank, which are national 
biobanks containing dried blood spot samples from new-
borns. For each medulloblastoma case, one control subject 
was identified among samples that were physically located 
close to the case sample in the biobanks. Control subjects 
were matched by date of birth (Swedish and Danish con-
trols) and sex (Danish controls only).
In Sweden, the study was approved by the Data Inspec-
tion Board and the Regional Ethical Review Board. All 
living Swedish subjects provided informed consent. The 
Regional Ethical Review Board approved the use of sam-
ples from deceased Swedish cases without informed consent 
from close relatives. In Denmark, the study was approved 
by the Research Ethics committee of the Capital Region 
(Copenhagen), the Danish Data Protection Agency, and by 
the Danish Newborn Screening Biobank Steering Commit-
tee. According to Danish law, the regional Ethics Committee 
can grant exemption from obtaining informed consent for 
research projects on biobank samples under certain circum-
stances [18]. For this study, such an exemption was granted.
The validation study included 249 cases and 629 controls 
originally recruited to four different studies: (1) Studies at 
Children’s Hospital Los Angeles and the USC Keck School 
of Medicine (CA, USA) [19], (2) a study conducted at Bay-
lor College of Medicine in Houston (TX, USA), (3) a study 
conducted at the University of Medical Sciences in Poznan, 
Poland, and (4) the CEFALO study conducted in Denmark, 
Sweden, Norway, and Switzerland [20] (Table S1). Ethical 
approval and informed consent from validation study sub-
jects were obtained at the respective study site.
Genotyping and imputation
DNA extraction and genotyping have previously been 
described in detail [16]. In brief, DNA was extracted using 
the Extract-N-amp kit (Sigma-Aldrich) [21–23] and was 
whole-genome-amplified using the REPLIg kit (QIAGEN; 
Danish subjects) or the GenomePlex Single Cell Whole 
Genome Amplification kit (Sigma-Aldrich; Swedish sub-
jects). Genotyping was performed using a high-density 
SNP-array (HumanOmni2.5–8 BeadChip, Illumina). Sub-
jects were excluded if their call-rate was less than 97% or 
if technical issues were identified, for example conflicting 
information on reported sex versus X chromosome geno-
types or the presence of unexpected duplicate samples. We 
also excluded subjects identified as outliers using principal 
component analysis [24, 25] (Figure S2). Based on these 
criteria, 20 cases and 17 controls were excluded (Figure 
S1). All subjects included in the association analyses were 
unrelated (PI-HAT < 0.2). SNPs were excluded based on 
call-rate (< 95%), minor allele frequency (MAF) (< 1%), 
and Hardy–Weinberg test (p < 1 × 10–4). We also excluded 
any A/T and C/G SNPs. Quality control was performed 
using PLINK (version 1.07, https ://zzz.bwh.harva rd.edu/
plink /) [26]. Imputation was based on 1,288,472 SNPs that 
passed quality control in the Swedish and Danish datasets 
and was performed using IMPUTE2 and SHAPEIT2 soft-
ware and data from the 1000 Genomes Project as reference 
[27–30]. Imputed SNPs with MAF < 1% or imputation info 
score < 0.8 were excluded from all subsequent analyses.
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In the validation phase of the study, we used the Seque-
nom iPLEX Gold platform when genotyping all subjects, 
except for control subjects from the study conducted at Chil-
dren’s Hospital Los Angeles and the USC Keck School of 
Medicine. These subjects were genotyped using Illumina 
BeadChips, and SNPs that were not represented on the 
arrays were imputed using MACH v1.0 and the HapMap 
phase 2 release 21 consensus CEU or CEU + ASN haplo-
types as reference.
Selection of SNPs
The genes APC, BRCA2, PALB2, PTCH1, SUFU, TP53, 
and GPR161 were selected for investigation using a candi-
date gene approach. The selection was based on two recent 
studies that found germline mutations in one of these genes 
in 6% of all medulloblastoma cases [3, 4]. The 1446 SNPs 
located within these genes include directly genotyped as well 
as imputed SNPs. We have previously reported the associa-
tion between genotyped variants in PTCH1 and TP53 and 
medulloblastoma risk based on the same study population 
[16].
Statistical methods
Association between genetic variants and medulloblastoma 
risk was assessed using a frequentist test under an additive 
model and the score method using SNPTEST v2.5.2 [31]. 
Analyses were adjusted for sex and five principal compo-
nents. Principal component analyses were conducted using 
EIGENSOFT version 6.1.4 (https ://www.hsph.harva rd.edu/
alkes -price /softw are/) [24, 25].
In the validation phase of the study, logistic regression 
analysis was preformed separately in two subsets of valida-
tion study subjects. Subset 1 included subjects from Chil-
dren’s Hospital Los Angeles and the USC Keck School of 
Medicine, and subset 2 included all other validation study 
subjects. The results from these two subsets were then com-
bined using fixed-effect model meta-analysis.
In genome-wide (agnostic) analyses, p < 5 × 10–8 was 
considered statistically significant. For candidate gene 
analyses, p < 0.007 was considered statistically significant, 
corresponding to Bonferroni correction for testing seven 
independent loci.
Acknowledgements Open access funding provided by Umeå Uni-
versity. We acknowledge the role of the late Dr. Mads V. Hollegaard 
in this study. Dr. Hollegaard was included in all parts of the study, 
with most important contributions in the conceptualization and formal 
analyses. The Cefalo Study Group includes Michaela Prochazka, Maral 
Adel Fahmideh, Birgitta Lannering, Lisbeth S. Schmidt, Christoffer 
Johansen, Astrid Sehested, Claudia Kuehni, Michael Grotzer, Tore 
Tynes, Tone Eggen, and Lars Klæboe. We are grateful for the sup-
port early in the study by Dr. Bent Nørgaard-Pedersen at the Danish 
Neonatal Screening Biobank and the assistance in sample collection 
by Dr. Ulrika von Döbeln at the Swedish phenylketonuria screening 
registry. This research was funded by the Swedish Childhood Cancer 
Foundation  (Grant Nos. NCS2009-0001, PR2017-0157, NC2011-
0004, and TJ2015-0044); the Acta Oncologica Foundation through 
The Royal Swedish Academy of Science; the Swedish Cancer Founda-
tion (Grant No. CAN 2018/390); the Swedish Research Council (Grant 
No. 2016-01159_3) ; the Cancer Research Foundation in Northern 
Sweden (Grant Nos. LP 14-2044, LP 10-1842); Umeå University 
Hospital (Cutting Edge Grant) (Grant Nos. 7002485, 7002994); and 
NIH-NIEHS grant, P30ES007033, R01CA116724 and R03CA106011. 
This research has been conducted using the Danish National Biobank 
resource, supported by the Novo Nordisk Foundation. Where authors 
are identified as personnel of the International Agency for Research on 
Cancer/World Health Organization, the authors alone are responsible 
for the views expressed in this article and they do not necessarily rep-
resent the decisions, policy or views of the International Agency for 
Research on Cancer/World Health Organization.
Author contributions Conceptualization, BM, UH, and AMD; meth-
odology, ID, CW and AMD; validation, MES, CCL, RMC, RJK, LTH, 
JY, ASM, JBT, WJG, MFe, JS, MR, KK, DJL, MFi, JN, SSN, and 
SA; formal analysis, AMD, and UA; resources, DMH; data curation, 
ID, AMD, and JBG; writing—original draft preparation, AMD; writ-
ing—review and editing, all authors; visualization, AMD; supervision, 
BM; project administration, UA, and LM; funding acquisition, BM, 
and AMD.
Data availability The datasets generated and/or analysed during the 
current study are not publicly available due to legal restrictions but 
are available from the corresponding author on reasonable request for 
researchers who meet the criteria for access to confidential data.
Compliance with ethical standards 
Conflict of interest The authors declare that they have no conflict of 
interest. The funders had no role in the design of the study; in the col-
lection, analyses, or interpretation of data; in the writing of the manu-
script, or in the decision to publish the results.
Ethical approval All procedures performed in studies involving human 
participants were in accordance with the ethical standards of institu-
tional and/or national research committee and with the 1964 Helsinki 
declaration and its later amendments.
Informed consent Informed consent was obtained from all Swedish 
living individual participants included in the discovery phase of the 
study. According to Danish law, the regional Ethics Committee can 
grant exemption from obtaining informed consent for research projects 
on biobank samples under certain circumstances. For the Danish arm 
of the discovery phase of this study, such an exemption was granted. 
Informed consent was obtained at the respective study site from par-
ticipants in the validation phase of the study.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
314 Journal of Neuro-Oncology (2020) 147:309–315
1 3
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. Hottinger AF, Khakoo Y (2009) Neurooncology of familial 
cancer syndromes. J Child Neurol 24:1526–1535. https ://doi.
org/10.1177/08830 73809 33753 9
 2. Smith MJ, Beetz C, Williams SG et al (2014) Germline muta-
tions in SUFU cause Gorlin syndrome-associated childhood 
medulloblastoma and redefine the risk associated with PTCH1 
mutations. J Clin Oncol 32:4155–4161. https ://doi.org/10.1200/
JCO.2014.58.2569
 3. Waszak SM, Northcott PA, Buchhalter I et al (2018) Spectrum 
and prevalence of genetic predisposition in medulloblastoma: a 
retrospective genetic study and prospective validation in a clinical 
trial cohort. Lancet Oncol 19:785–798. https ://doi.org/10.1016/
S1470 -2045(18)30242 -0
 4. Begemann M, Waszak SM, Robinson GW et al (2020) Germline 
GPR161 mutations predispose to pediatric medulloblastoma. J 
Clin Oncol 38:43–50. https ://doi.org/10.1200/JCO.19.00577 
 5. Northcott PA, Korshunov A, Pfister SM, Taylor MD (2012) The 
clinical implications of medulloblastoma subgroups. Nat Rev 
Neurol 8:340–351. https ://doi.org/10.1038/nrneu rol.2012.78
 6. Weil AG, Wang AC, Westwick HJ et al (2017) Survival in pedi-
atric medulloblastoma: a population-based observational study to 
improve prognostication. J Neurooncol 132:99–107. https ://doi.
org/10.1007/s1106 0-016-2341-4
 7. De Braganca KC, Packer RJ (2013) Treatment options for medul-
loblastoma and CNS primitive neuroectodermal tumor (PNET). 
Curr Treat Options Neurol 15:593–606. https ://doi.org/10.1007/
s1194 0-013-0255-4
 8. Raynor LA, Pankratz N, Spector LG (2013) An analysis of meas-
ures of effect size by age of onset in cancer genomewide associa-
tion studies. Genes Chromosom Cancer 52:855–859. https ://doi.
org/10.1002/gcc.22081 
 9. Craig SE, Brady-Kalnay SM (2015) Regulation of development 
and cancer by the R2B subfamily of RPTPs and the implications 
of proteolysis. Semin Cell Dev Biol 37:108–118. https ://doi.
org/10.1016/j.semcd b.2014.09.004
 10. Brady-Kalnay SM, Rimm DL, Tonks NK (1995) Receptor pro-
tein tyrosine phosphatase PTPmu associates with cadherins and 
catenins in vivo. J Cell Biol 130:977–986. https ://doi.org/10.1083/
jcb.130.4.977
 11. Couch FJ, Shimelis H, Hu C et al (2017) Associations between 
cancer predisposition testing panel genes and breast cancer. 
JAMA Oncol 3:1190–1196. https ://doi.org/10.1001/jamao 
ncol.2017.0424
 12. Manahan ER, Kuerer HM, Sebastian M et al (2019) Consensus 
guidelines on genetic` testing for hereditary breast cancer from the 
American Society of Breast Surgeons. Ann Surg Oncol 26:3025–
3031. https ://doi.org/10.1245/s1043 4-019-07549 -8
 13. Melin BS, Barnholtz-Sloan JS, Wrensch MR et al (2017) Genome-
wide association study of glioma subtypes identifies specific dif-
ferences in genetic susceptibility to glioblastoma and non-glio-
blastoma tumors. Nat Genet 49:789–794. https ://doi.org/10.1038/
ng.3823
 14. Labreche K, Kinnersley B, Berzero G et al (2018) Diffuse glio-
mas classified by 1p/19q co-deletion, TERT promoter and IDH 
mutation status are associated with specific genetic risk loci. 
Acta Neuropathol 135:743–755. https ://doi.org/10.1007/s0040 
1-018-1825-z
 15. Shete S, Hosking FJ, Robertson LB et al (2009) Genome-wide 
association study identifies five susceptibility loci for glioma. Nat 
Genet 41:899–904. https ://doi.org/10.1038/ng.407
 16. Dahlin AM, Hollegaard MV, Wibom C et al (2015) CCND2, 
CTNNB1, DDX3X, GLI2, SMARCA4, MYC, MYCN, PTCH1, 
TP53, and MLL2 gene variants and risk of childhood medullo-
blastoma. J Neurooncol 125:75–78. https ://doi.org/10.1007/s1106 
0-015-1891-1
 17. Hannelius U, Lindgren CM, Melen E et al (2005) Phenylketonuria 
screening registry as a resource for population genetic studies. J 
Med Genet 42:e60. https ://doi.org/10.1136/jmg.2005.03298 7
 18. Norgaard-Pedersen B, Hougaard DM (2007) Storage policies and 
use of the Danish Newborn Screening Biobank. J Inherit Metab 
Dis 30:530–536. https ://doi.org/10.1007/s1054 5-007-0631-x
 19. Torgerson DG, Ampleford EJ, Chiu GY et al (2011) Meta-anal-
ysis of genome-wide association studies of asthma in ethnically 
diverse North American populations. Nat Genet 43:887–892. https 
://doi.org/10.1038/ng.888
 20. Aydin D, Feychting M, Schuz J et al (2011) Mobile phone use 
and brain tumors in children and adolescents: a multicenter case-
control study. J Natl Cancer Inst 103:1264–1276. https ://doi.
org/10.1093/jnci/djr24 4
 21. Hollegaard MV, Grauholm J, Borglum A et al (2009) Genome-
wide scans using archived neonatal dried blood spot samples. BMC 
Genomics 10:297. https ://doi.org/10.1186/1471-2164-10-297
 22. Hollegaard MV, Grove J, Grauholm J et  al (2011) Robust-
ness of genome-wide scanning using archived dried blood 
spot samples as a DNA source. BMC Genet 12:58. https ://doi.
org/10.1186/1471-2156-12-58
 23. Hollegaard MV, Thorsen P, Norgaard-Pedersen B, Hougaard DM 
(2009) Genotyping whole-genome-amplified DNA from 3- to 
25-year-old neonatal dried blood spot samples with reference to 
fresh genomic DNA. Electrophoresis 30:2532–2535. https ://doi.
org/10.1002/elps.20080 0655
 24. Price AL, Patterson NJ, Plenge RM et al (2006) Principal compo-
nents analysis corrects for stratification in genome-wide associa-
tion studies. Nat Genet 38:904–909. https ://doi.org/10.1038/ng184 
7
 25. Patterson N, Price AL, Reich D (2006) Population structure and 
eigenanalysis. PLoS Genet 2:e190. https ://doi.org/10.1371/journ 
al.pgen.00201 90
 26. Purcell S, Neale B, Todd-Brown K et al (2007) PLINK: a tool set 
for whole-genome association and population-based linkage anal-
yses. Am J Hum Genet 81:559–575. https ://doi.org/10.1086/51979 
5
 27. Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR 
(2012) Fast and accurate genotype imputation in genome-wide 
association studies through pre-phasing. Nat Genet 44:955–959. 
https ://doi.org/10.1038/ng.2354
 28. Howie B, Marchini J, Stephens M (2011) Genotype imputation 
with thousands of genomes. G3 (Bethesda) 1: 457–470. https ://
doi.org/10.1534/g3.111.00119 8
 29. Howie BN, Donnelly P, Marchini J (2009) A flexible and accurate 
genotype imputation method for the next generation of genome-
wide association studies. PLoS Genet 5:e1000529. https ://doi.
org/10.1371/journ al.pgen.10005 29
 30. Delaneau O, Marchini J, Zagury JF (2011) A linear complexity 
phasing method for thousands of genomes. Nat Methods 9:179–
181. https ://doi.org/10.1038/nmeth .1785
 31. Marchini J, Howie B, Myers S, McVean G, Donnelly P (2007) 
A new multipoint method for genome-wide association studies 
by imputation of genotypes. Nat Genet 39:906–913. https ://doi.
org/10.1038/ng208 8
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
315Journal of Neuro-Oncology (2020) 147:309–315 
1 3
Affiliations
Anna M. Dahlin1  · Carl Wibom1 · Ulrika Andersson1 · Jonas Bybjerg‑Grauholm2 · Isabelle Deltour3,4 · 
David M. Hougaard2 · Michael E. Scheurer5 · Ching C. Lau5 · Roberta McKean‑Cowdin6 · Rebekah J. Kennedy7 · 
Long T. Hung8 · Janis Yee8 · Ashley S. Margol8 · Jessica Barrington‑Trimis6 · W. James Gauderman6 · 
Maria Feychting9 · Joachim Schüz3 · Martin Röösli10,11 · Kristina Kjaerheim12 · The Cefalo Study Group · 
Danuta Januszkiewicz‑Lewandowska13,14 · Marta Fichna15 · Jerzy Nowak13 · Susan Searles Nielsen16,17 · 
Shahab Asgharzadeh8,18 · Lisa Mirabello19 · Ulf Hjalmars1 · Beatrice Melin1
1 Department of Radiation Sciences, Oncology, Umeå 
University, Umeå, Sweden
2 Danish Center for Neonatal Screening, Department 
for Congenital Disorders, Statens Serum Institut, 
Copenhagen, Denmark
3 Section of Environment and Radiation, International Agency 
for Research on Cancer, Lyon, France
4 Unit of Statistics, Bioinformatics and Registry, Danish 
Cancer Society Research Center, Copenhagen, Denmark
5 Department of Pediatrics, Section of Hematology-Oncology, 
Texas Children’s Cancer Center, Baylor College of Medicine, 
Houston, TX, USA
6 Department of Preventive Medicine, Keck School 
of Medicine, University of Southern California, Los Angeles, 
CA, USA
7 Children’s Center for Cancer and Blood Diseases, Children’s 
Hospital Los Angeles, Los Angeles, CA, USA
8 Department of Pediatrics, Section of Hematology-Oncology, 
Children’s Hospital Los Angeles and The Saban Research 
Institute, Keck School of Medicine of University of Southern 
California, Los Angeles, CA, USA
9 Unit of Epidemiology, Institute of Environmental Medicine, 
Karolinska Institutet, Stockholm, Sweden
10 Department of Epidemiology and Public Health, Swiss 
Tropical and Public Health Institute, Basel, Switzerland
11 University of Basel, Basel, Switzerland
12 The Cancer Registry of Norway, Oslo, Norway
13 Institute of Human Genetics, Polish Academy of Sciences, 
Poznan, Poland
14 Department of Pediatric Oncology, Hematology and Bone 
Marrow Transplantation, Poznan University of Medical 
Sciences, Poznan, Poland
15 Department of Endocrinology, Metabolism and Internal 
Medicine, Poznan University of Medical Sciences, Poznan, 
Poland
16 Public Health Sciences Division, Fred Hutchinson Cancer 
Research Center, Seattle, WA, USA
17 Department of Neurology, School of Medicine, University 
of Washington, Seattle, WA, USA
18 Department of Pathology, Saban Research Institute 
at Children’s Hospital Los Angeles, Keck School 
of Medicine, University of Southern California, Los Angeles, 
CA, USA
19 Division of Cancer Epidemiology and Genetics, National 
Cancer Institute, National Institutes of Health, Bethesda, 
MD, USA
